Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 8, 2026 · Investor press release · Financial statements
Vor Biopharma Inc.
8
Investor press release
Jun 8, 2026
| Form type | Current report (Form 8-K) |
| Event summary | Investor press release · Financial statements |
| Primary topic | Investor press release |
| About this form | Public companies file this within four business days when something important happens that investors should know about, before the next quarterly report. |
| Why this was filed | Vor Biopharma Inc. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England Journal of Medicine IgAN marks the fourth indicatio… |
| Labor angle | Watch for Item 2.05 (restructuring or severance), Item 5.02 (leadership changes), and Item 1.01 (major contracts that can precede workforce shifts). |
| Period of report | Jun 8, 2026 |
| Accession number | 0001193125-26-261661 |
| Reported items | Regulation FD disclosure (investor press release or presentation), Financial statements and exhibits See Analysis tab for workforce implications |
